Trials in Los Angeles, California
Here are the top 10 medical studies for lung cancer in Los Angeles, California
Popular Filters
Phase 3 Trials
Monoclonal Antibodies
Trastuzumab Deruxtecan for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Los Angeles, California
This trial will compare the effectiveness and safety of Trastuzumab Deruxtecan to the current standard of care for treating non-small cell lung cancer with HER2 Exon 19 or 20 mutations.
Monoclonal Antibodies
Pembrolizumab SC vs IV for Lung Cancer
Recruiting2 awardsPhase 3
Whittier, California
This trial is testing a new way to give the cancer drug pembrolizumab as an injection under the skin for people with advanced lung cancer. The goal is to see if this method works as well as the traditional IV method. The study will also check if it is safe and effective when used with standard chemotherapy.
Chemotherapy
Radiation + Immunotherapy for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 2 & 3
Upland, California
This trial is testing the addition of radiation therapy to the usual immunotherapy (with or without chemotherapy) treatment for patients with non-small cell lung cancer that has spread to nearby tissue or lymph nodes (advanced) or has spread to other places in the body (metastatic) and who are also negative for a molecular marker called PD-L1.
Monoclonal Antibodies
Telisotuzumab Vedotin vs. Docetaxel for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Los Angeles, California
This trial is testing a new drug called telisotuzumab vedotin to see if it can treat a specific type of lung cancer better than an existing drug. The study focuses on adults whose lung cancer has not responded to previous treatments. The new drug targets and kills cancer cells by attaching to a specific protein on their surface.
Immunostimulant
Combination Immunotherapy for Lung Cancer
Recruiting1 awardPhase 2 & 3
Los Angeles, California
This trial is testing a new combination of treatments for patients with advanced lung cancer. The treatments aim to boost the immune system's ability to fight cancer and prevent it from growing. The goal is to see if this combination can help patients live longer compared to standard treatments.
Trials With No Placebo
Monoclonal Antibodies
Trastuzumab Deruxtecan for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Los Angeles, California
This trial will compare the effectiveness and safety of Trastuzumab Deruxtecan to the current standard of care for treating non-small cell lung cancer with HER2 Exon 19 or 20 mutations.
Immunotherapy
ABBV-514 + Budigalimab for Lung & Head and Neck Cancers
Recruiting1 awardPhase 1
Fullerton, California
This trial is testing two experimental drugs, ABBV-514 and Budigalimab, on adults with specific types of cancer. The goal is to find out if these drugs can help treat lung and head/neck cancers by monitoring their effects and side effects.
Cytokine
NT-I7 + Atezolizumab for Lung Cancer
Recruiting1 awardPhase 2
Cerritos, California
This trial will test the effectiveness of a new cancer treatment in people with squamous or non-squamous non-small cell lung cancer who haven't received prior systemic therapy. Up to 83 people will be enrolled in the study.
Monoclonal Antibodies
Pembrolizumab SC vs IV for Lung Cancer
Recruiting2 awardsPhase 3
Whittier, California
This trial is testing a new way to give the cancer drug pembrolizumab as an injection under the skin for people with advanced lung cancer. The goal is to see if this method works as well as the traditional IV method. The study will also check if it is safe and effective when used with standard chemotherapy.
Chemotherapy
Radiation + Immunotherapy for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 2 & 3
Upland, California
This trial is testing the addition of radiation therapy to the usual immunotherapy (with or without chemotherapy) treatment for patients with non-small cell lung cancer that has spread to nearby tissue or lymph nodes (advanced) or has spread to other places in the body (metastatic) and who are also negative for a molecular marker called PD-L1.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.